MA54741A - Composés thiényl-aniline destinés au traitement d'affections de la peau - Google Patents
Composés thiényl-aniline destinés au traitement d'affections de la peauInfo
- Publication number
- MA54741A MA54741A MA054741A MA54741A MA54741A MA 54741 A MA54741 A MA 54741A MA 054741 A MA054741 A MA 054741A MA 54741 A MA54741 A MA 54741A MA 54741 A MA54741 A MA 54741A
- Authority
- MA
- Morocco
- Prior art keywords
- thienyl
- treatment
- skin conditions
- aniline compounds
- aniline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769832P | 2018-11-20 | 2018-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54741A true MA54741A (fr) | 2021-11-24 |
Family
ID=70773567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054741A MA54741A (fr) | 2018-11-20 | 2019-11-20 | Composés thiényl-aniline destinés au traitement d'affections de la peau |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12466818B2 (fr) |
| EP (1) | EP3911313A4 (fr) |
| JP (1) | JP7546297B2 (fr) |
| CN (2) | CN113498340A (fr) |
| AU (1) | AU2019384645B2 (fr) |
| CA (1) | CA3120352A1 (fr) |
| MA (1) | MA54741A (fr) |
| WO (1) | WO2020106305A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3120351A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau |
| WO2020106308A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau |
| WO2020106306A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| WO2020106305A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés thiényl-aniline destinés au traitement d'affections de la peau |
| US11010862B1 (en) * | 2019-11-14 | 2021-05-18 | Advanced Micro Devices, Inc. | Reduced bandwidth tessellation factors |
| IL312977A (en) | 2021-11-23 | 2024-07-01 | Nflection Therapeutics Inc | Formulations of pyrrolopyridine-aniline compounds |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271164A (en) | 1979-04-16 | 1981-06-02 | Warner-Lambert Company | 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives |
| GB9420168D0 (en) | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| BR9810385A (pt) | 1997-07-01 | 2000-09-05 | Warner Lambert Co | Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek |
| JP2910748B2 (ja) | 1997-11-12 | 1999-06-23 | 日本電気株式会社 | 異質同軸部材の端面の球状加工装置及びその方法 |
| DE69926914T2 (de) | 1999-01-13 | 2006-06-29 | Warner-Lambert Co. Llc | 1-heterozyklus-substituierte diarylaminen |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| WO2003090688A2 (fr) | 2002-04-24 | 2003-11-06 | Van Andel Research Institute | Accentuation de la melanogenese epidermique chez l'homme |
| AU2003251661A1 (en) | 2002-08-06 | 2004-02-25 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| EP1742627A4 (fr) * | 2004-05-06 | 2009-08-26 | Plexxikon Inc | Inhibiteurs de pde4b et leurs utulisations |
| SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| ZA200703912B (en) | 2004-10-20 | 2008-09-25 | Serono Lab | 3-arylamino pyridine derivatives |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| US7772233B2 (en) | 2006-04-19 | 2010-08-10 | Merck Serono, S.A. | Arylamino N-heteroaryl compounds as MEK inhibitors |
| GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| CN101528231A (zh) * | 2006-08-16 | 2009-09-09 | 埃克塞利希斯股份有限公司 | 在癌症的治疗中使用pi3k和mek调控剂 |
| AU2007286808B2 (en) | 2006-08-21 | 2012-12-06 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| DK2086504T3 (da) | 2006-10-17 | 2014-04-07 | Nuvo Res Inc | Diclofenac-gel |
| EP2089359A2 (fr) | 2006-10-31 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase mapk/erk |
| PE20081354A1 (es) | 2006-11-30 | 2008-11-14 | Genentech Inc | Compuestos de azaindolilo como inhibidores de mek |
| US20090082328A1 (en) | 2007-05-11 | 2009-03-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity |
| US20080312307A1 (en) | 2007-05-25 | 2008-12-18 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| CA2708176A1 (fr) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines et procedes d'utilisation |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| EP2240494B1 (fr) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| EP2440204B1 (fr) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Composés de nicotinamide utiles en tant que modulateurs de kinases |
| DE102010012594A1 (de) | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| WO2012040636A2 (fr) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase |
| MX341471B (es) | 2010-11-05 | 2016-08-22 | Hoffmann La Roche | Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central. |
| WO2012099968A1 (fr) | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions et procédés de traitement de maladies associées à un cancer de la peau |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| WO2012171484A1 (fr) | 2011-06-17 | 2012-12-20 | 中国中化股份有限公司 | Composés de cyanoaniline substitués, leur préparation et leur utilisation |
| WO2014179785A1 (fr) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Répulsifs améliorés contre les abeilles domestiques et leurs utilisations |
| WO2014210538A1 (fr) | 2013-06-28 | 2014-12-31 | The Regents Of The University Of California | Traitement des déficits cognitifs associés au syndrome de noonan |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| JP2018535238A (ja) | 2015-11-30 | 2018-11-29 | イグナイタ インコーポレイテッド | 局所製剤 |
| EP3301094A1 (fr) | 2016-09-30 | 2018-04-04 | Mutabilis | Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes |
| JP7237941B2 (ja) | 2017-05-19 | 2023-03-13 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置用の融合複素環式芳香族アニリン化合物 |
| PT3624796T (pt) | 2017-05-19 | 2025-06-02 | Nflection Therapeutics Inc | Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos |
| US11395823B2 (en) | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
| WO2020101878A2 (fr) | 2018-10-29 | 2020-05-22 | The Johns Hopkins University | Traitement de rasopathie |
| WO2020106304A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Formulations topiques |
| WO2020106305A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés thiényl-aniline destinés au traitement d'affections de la peau |
| WO2020106306A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| EP4233834A3 (fr) | 2018-11-20 | 2023-10-25 | NFlection Therapeutics, Inc. | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |
| WO2020106308A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau |
| CA3120351A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau |
| IL301496A (en) | 2020-09-24 | 2023-05-01 | Nflection Therapeutics Inc | Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds |
| JP2024503893A (ja) | 2021-01-21 | 2024-01-29 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン－アニリン化合物を調製するための方法 |
| EP4281055A4 (fr) | 2021-01-21 | 2025-06-18 | NFlection Therapeutics, Inc. | Formes cristallines d'un composé de pyrrolopyridine-aniline |
-
2019
- 2019-11-20 WO PCT/US2019/000067 patent/WO2020106305A1/fr not_active Ceased
- 2019-11-20 EP EP19887349.9A patent/EP3911313A4/fr active Pending
- 2019-11-20 CA CA3120352A patent/CA3120352A1/fr active Pending
- 2019-11-20 MA MA054741A patent/MA54741A/fr unknown
- 2019-11-20 AU AU2019384645A patent/AU2019384645B2/en active Active
- 2019-11-20 JP JP2021527910A patent/JP7546297B2/ja active Active
- 2019-11-20 CN CN201980089585.XA patent/CN113498340A/zh active Pending
- 2019-11-20 CN CN202311548396.9A patent/CN117551073A/zh active Pending
- 2019-11-20 US US17/294,779 patent/US12466818B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022510586A (ja) | 2022-01-27 |
| EP3911313A4 (fr) | 2022-10-12 |
| JP7546297B2 (ja) | 2024-09-06 |
| EP3911313A1 (fr) | 2021-11-24 |
| CN117551073A (zh) | 2024-02-13 |
| CA3120352A1 (fr) | 2020-05-28 |
| US12466818B2 (en) | 2025-11-11 |
| CN113498340A (zh) | 2021-10-12 |
| AU2019384645A1 (en) | 2021-06-10 |
| WO2020106305A1 (fr) | 2020-05-28 |
| US20220204486A1 (en) | 2022-06-30 |
| AU2019384645B2 (en) | 2025-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EP3911313A4 (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| EP3448389A4 (fr) | Composés de quinazoline et d'indole destinés au traitement de troubles médicaux | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| IL281809A (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| MA55144A (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| EP3784260A4 (fr) | Compositions pour le traitement d'affections cutanées | |
| EP3883553A4 (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| EP3950686A4 (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| EP3852745A4 (fr) | Composés destinés au traitement de certaines leucémies | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3790563A4 (fr) | Compositions permettant le traitement d'affections cutanées | |
| EP3664812A4 (fr) | Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée | |
| EP3883552A4 (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3672587A4 (fr) | Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques | |
| EP3959213C0 (fr) | Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau | |
| EP3773632A4 (fr) | Méthodes de traitement de glioblastomes exprimant l'egfrviii | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| MA51738A (fr) | Composés pour le traitement de la douleur |